NovoCure Ltd (NVCR)
About NovoCure Ltd
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $655.4M
- Net income
- -$136.2M
- Total assets
- $804.3M
- Market cap
- $2.0B
- Gross margin
- 74.5%
- Operating margin
- -23.5%
- Net margin
- -20.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $655.4M
- Cost of revenue
- $166.9M
- Gross profit
- $488.5M
- Operating expenses
- $642.3M
- Operating income
- -$153.8M
- Income tax
- -$23.0K
- Net income
- -$136.2M
- EPS (basic)
- $-1.22
- EPS (diluted)
- $-1.22
Balance sheet
- Total assets
- $804.3M
- Current assets
- $646.7M
- Total liabilities
- $463.9M
- Current liabilities
- $223.2M
- Shareholders’ equity
- $340.5M
Cash flow
- Operating cash flow
- -$49.0M
- Investing cash flow
- $437.3M
- Financing cash flow
- -$451.3M
- Net cash flow
- -$62.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $2.0B
- EPS (diluted)
- $-1.22
- Shares outstanding
- 112.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 2, 2015
NovoCure Ltd (NVCR) Stock Price
- Reported a net loss of $136.2M in FY2025.
- Revenue grew 33% from FY2020 to FY2025.
- Gross margin of 74.5%, net margin -20.8%.
- Trading 12% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review NovoCure Ltd.
Write a review
News about NovoCure Ltd
News & sentiment via Polygon.io
NovoCure Ltd: frequently asked questions
Is NovoCure Ltd an American company?
NovoCure Ltd is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is NovoCure Ltd publicly traded?
Yes — NovoCure Ltd is a publicly traded company. Its stock trades under the ticker symbol NVCR on the NASDAQ.
What does NovoCure Ltd do?
NovoCure Ltd is an American Medical Devices company in the Health & Beauty sector.
